

Insomnia With Objective Short Sleep Duration Is Associated With Type 2 Diabetes

A population-based study

ALEXANDROS N. VGONTZAS, MD¹
DUANPING LIAO, MD, PHD²
SLOBODANKA PEJOVIC, MD¹

SUSAN CALHOUN, PHD¹
MARIA KARATARAKI, PSYCHD¹
EDWARD O. BIXLER, PHD¹

OBJECTIVE — We examined the joint effects of insomnia and objective short sleep duration, the combination of which is associated with higher morbidity, on diabetes risk.

RESEARCH DESIGN AND METHODS — A total of 1,741 men and women randomly selected from Central Pennsylvania were studied in the sleep laboratory. Insomnia was defined by a complaint of insomnia with duration of ≥ 1 year, whereas poor sleep was defined as a complaint of difficulty falling asleep, staying asleep, or early final awakening. Polysomnographic sleep duration was classified into three categories: ≥ 6 h of sleep (top 50% of the sample); 5–6 h (approximately third quartile of the sample); and ≤ 5 h (approximately the bottom quartile of the sample). Diabetes was defined either based on a fasting blood glucose > 126 mg/dl or use of medication. In the logistic regression model, we simultaneously adjusted for age, race, sex, BMI, smoking, alcohol use, depression, sleep-disordered breathing, and periodic limb movement.

RESULTS — Chronic insomnia but not poor sleep was associated with a higher risk for diabetes. Compared with the normal sleeping and ≥ 6 h sleep duration group, the highest risk of diabetes was in individuals with insomnia and ≤ 5 h sleep duration group (odds ratio [95% CI] 2.95 [1.2–7.0]) and in insomniacs who slept 5–6 h (2.07 [0.68–6.4]).

CONCLUSIONS — Insomnia with short sleep duration is associated with increased odds of diabetes. Objective sleep duration may predict cardiometabolic morbidity of chronic insomnia, the medical impact of which has been underestimated.

Diabetes Care 32:1980–1985, 2009

Many studies have established that insomnia, the most common sleep disorder, is highly comorbid with psychiatric disorders and is a risk factor for the development of depression, anxiety, and suicide (1,2). In contrast with sleep-disordered breathing (SDB), the second most common sleep disorder, chronic insomnia has not been associated with significant medical morbidity, e.g., cardiovascular disorders (3,4).

Recently, we demonstrated that insomnia with objective short sleep dura-

tion is associated with a high risk for hypertension (5). These data suggest that objective sleep measures in insomnia provide an index of the severity of the disorder and that the more severe form of insomnia is most likely associated with morbidity and possibly mortality. This hypothesis is further supported by physiological studies, which demonstrated that activation of the hypothalamic-pituitary-adrenal (HPA) axis and autonomic system, including increased heart rate, 24-h metabolic rate, and impaired

heart rate variability, is present in insomniacs who meet both subjective and objective polysomnographic criteria (6–11). Given the association of the HPA axis and sympathetic system activation with the pathogenesis of metabolic disorders, including diabetes (12), we hypothesized that insomnia with objective short sleep duration will be associated with type 2 diabetes.

Previous studies have shown that sleep disturbances or complaints are associated with increased incidence of type 2 diabetes (13–16). However, in these studies, the presence of sleep disturbances was based only on a subjective questionnaire and did not control for obstructive sleep apnea, a sleep disorder whose association with diabetes and insulin resistance is well established (12). Thus, it is not known whether insomnia per se is associated with an increased risk for diabetes.

To test this hypothesis, we examined the joint effects of the complaints of chronic insomnia and poor sleep (a milder form of insomnia) and objective sleep duration on the prevalence of diabetes in a large cross-sectional population-based sample from Central Pennsylvania (Penn State Cohort).

RESEARCH DESIGN AND METHODS

The data were collected as part of a two-phase protocol whose primary purpose was to establish the age distribution of SDB (17,18). In the first phase of the study, a sample of adult men and women (aged ≥ 20 years) was randomly selected from local telephone households in two counties of Central Pennsylvania (Dauphin and Lebanon) using the Mitofsky-Waksberg two-stage random digit dialing procedure. A within-household selection procedure described by Kish was used to select the specific man or woman to be interviewed. Telephone interviews were conducted with 4,364 age-eligible men and 12,219 age-eligible women residing in the sample households for a total sample of 16,583 with response rates of 73.5 and 74.1%, respectively. The question-

From the ¹Sleep Research and Treatment Center, Department of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and the ²Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.

Corresponding author: Alexandros N. Vgontzas, avgontzas@psu.edu.

Received 13 February 2009 and accepted 13 July 2009. Published ahead of print at <http://care.diabetesjournals.org> on 29 July 2009. DOI: 10.2337/dc09-0284.

© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

naire used in this interview included basic demographic and sleep information.

In the second phase of this study, a subsample of 741 men and 1,000 women selected from those subjects previously interviewed by telephone were studied in our sleep laboratory. The sample of men was chosen by counting how many of four risk factors (snoring, daytime sleepiness, obesity, and hypertension) each interviewed subject reported. Subjects with higher counts of risk factors were oversampled (3, 9, 32, 45, and 70% for 0, 1, 2, 3, and 4 symptoms reported, respectively). The sample of women was chosen by counting how many of five risk factors (snoring, daytime sleepiness, obesity, hypertension, and menopause) were reported by each interviewed subject. Those with higher counts of risk factors were oversampled (2, 4, 10, 27, 51, and 56% of those with 0, 1, 2, 3, 4, and 5 symptoms reported, respectively). The response rates for this phase were 67.8 and 65.8% for men and women, respectively. There were no significant differences between those subjects who were recorded in the laboratory and those who were selected but were not recorded in terms of age, BMI, reported use of medication for hypertension or diabetes, and prevalence of sleep disorders. Each subject selected for laboratory evaluation completed a comprehensive sleep history and physical examination and was continuously monitored for one night for 8 h using 16-channel polygraphs including an electroencephalogram, electrooculogram, and electromyogram. Bedtimes were adjusted to conform to subjects' usual bedtimes, and recordings were done between 10:00 and 11:00 P.M. and 6:00 and 7:00 A.M. The sleep records were subsequently scored independently according to standardized criteria. Percent sleep time is total sleep time (duration of sleep) divided by recorded time in bed and multiplied by 100. Respiration was monitored throughout the night by use of thermocouples at the nose and mouth and thoracic strain gauges. All-night recordings of hemoglobin oxygen saturation (SaO₂) were obtained with an oximeter attached to the finger.

Key measurements

Diabetes was defined as being medically treated for diabetes or having fasting blood glucose >126 mg/dl from blood drawn the morning after the sleep laboratory testing. Hypertension was defined as diastolic blood pressure >90 mmHg or

systolic blood pressure >140 mmHg at the time of the sleep laboratory evaluation or the use of antihypertension medication.

The presence of sleep disorders was based on a standardized questionnaire completed by the subjects on the evening of their sleep laboratory visit. This questionnaire consists of 53 questions (7 demographic, 20 sleep-related, and 26 general health questions). In addition, women responded to eight questions related to menstrual history, menopause, and hormone therapy (for more details, see ref. 5). The presence of sleep difficulty was established on three levels of severity. First, insomnia was defined by a complaint of insomnia with a duration of at least 1 year. Second, poor sleep was defined as a moderate to severe complaint (based on a mild to severe scale) of difficulty falling asleep, difficulty staying asleep, early final awakening, or unrefreshing sleep. To create two mutually exclusive categories, the insomnia group could include those who reported one or more of the four symptoms of poor sleep, whereas none of the poor sleep group had a complaint of insomnia. Third, normal sleeping was defined as the absence of either of these two categories.

From the objectively recorded sleep time data, we regrouped the entire study sample into three ordinal groups based on standard mathematical approaches using as cutoff points the 50th percentile and the 25th percentile: the top 50% of persons above the median percent sleep time ("normal sleep duration group"), the 25% of persons in the third quartile ("moderately short sleep duration group"), and the bottom 25% of persons ("severely short sleep duration group"). We then rounded the quartile cutoff points to practically meaningful numbers. Thus, we created the following three relative sleep duration groups: the normal sleep duration group consisted of those who slept >6 h, the moderately short sleep duration group consisted of those who slept 5–6 h, and the severely short sleep duration group consisted of those who slept ≤5 h.

To control for possible confounding variables influencing the relation between insomnia and diabetes in the subsample of 1,741, we ascertained whether the respondent was currently treated for depression (including a history of suicidal thoughts or attempts), had a history of smoking (current use of any type of tobacco product), had a history of alcohol

use (more than two alcohol drinks per day), and had sleep apnea or periodic limb movements. For the purpose of this study, sleep apnea was defined as an obstructive apnea or hypopnea index of ≥5 (5,17,18). The condition of periodic limb movement was considered present when there were five or more movements per hour of sleep, and leg movements were scored according to standardized criteria (5). BMI was based on measured height (centimeters) and weight (kilograms) during the subjects' sleep laboratory visit, and data are presented in terms of mean, percentile distribution, and prevalence within each category.

Statistical analyses

The design of this study included oversampling of those at higher risk for SDB and women with markedly higher levels of BMI to increase the precision of the risk estimates. Because of this sampling strategy, numeric sampling weights were developed for the analysis so that the estimates could be inferred to the original target population (5,17,18). Specifically, three weights were created for the men. First, in the telephone sample, 32 of the 963 clusters of phone numbers in the first stage were "exhausted" before the target sample size was obtained. A compensatory weight was computed that corrected for this problem. A second weight was computed because the within-household screening deliberately introduced unequal probabilities of selection across the three age-groups to oversample the middle age-group. The final weight for the men was computed to account for the oversampling of subjects for the sleep laboratory study (phase II); those with larger counts of the four possible risk factors, i.e., snoring, daytime sleepiness, obesity, and hypertension, had substantially higher probability of being selected. For the women, the only weight required was to account for the oversampling of subjects for the sleep laboratory study. To eliminate any suggestion of possible sample bias, we calculated 32 unique weights for the women and 16 unique weights for the men corresponding to all possible combinations of the five risk factors for the women and four for the men. Any individual weight that had too small of a cell size was combined with adjacent cells so that <10% of the cells had a sample <25, and no cell had a size <10. Finally, we used the BMI and race distributions by age decade from the National Health and Nutrition Examination Survey III labora-

Table 1—Demographic, clinical, and sleep characteristics of the study population

| | Diabetes | | | Sleep difficulty | | | | Sleep duration (h) | | |
|------------------------------------------|--------------|-------------|------------|------------------|--------------|-------------|--------------|--------------------|-------------|--|
| | All | No | Yes | Normal sleeping | Poor sleep | Insomnia | ≤5 | 5–6 | >6 | |
| n | 1,741 | 1,327 | 414 | 1,022 | 520 | 199 | 449 | 430 | 862 | |
| Age (years) | 48.7 ± 13.52 | 47.3 ± 14.2 | 57.1 ± 8.6 | 49.3 ± 14.9 | 46.5 ± 11.56 | 49.9 ± 9.88 | 58.3 ± 11.78 | 51.4 ± 13.12 | 44.0 ± 12.0 | |
| BMI | 27.6 ± 5.67 | 27.0 ± 5.6 | 31.2 ± 5.1 | 27.0 ± 5.52 | 28.8 ± 5.57 | 29.0 ± 6.11 | 28.06 ± 5.40 | 27.8 ± 5.44 | 27.1 ± 2.89 | |
| BMI percentile | | | | | | | | | | |
| 25th | 24.0 | 23.5 | 25.2 | 23.8 | 24.6 | 23.4 | 23.8 | 24.2 | 24.2 | |
| 50th | 26.2 | 25.5 | 28.3 | 26.0 | 27.3 | 27.7 | 26.2 | 26.6 | 26.5 | |
| 75th | 30.2 | 28.6 | 32.5 | 29.3 | 31.9 | 32.6 | 29.8 | 30.3 | 30.9 | |
| Obesity (BMI ≥30 kg/m ²) (%) | 26 | 19 | 39 | 21 | 35 | 40 | 24 | 27 | 29 | |
| Sex (% male) | 48 | 44 | 72 | 53 | 37 | 26 | 59 | 50 | 42 | |
| Ethnicity (% white) | 86 | 86 | 87 | 86 | 87 | 76 | 93 | 85 | 83 | |
| Diabetes (%) | 14 | — | — | 13 | 15 | 18 | 22 | 18 | 9 | |
| Glucose (mg/dl) | 104 ± 35 | 93 ± 14 | 164 ± 43 | 103 ± 38 | 103 ± 29 | 109 ± 32 | 114 ± 38 | 107 ± 36 | 98 ± 31 | |
| Current smoker (%) | 26 | 25 | 27 | 27 | 27 | 21 | 26 | 21 | 27 | |
| Current alcohol consumption (%) | 16 | 17 | 15 | 19 | 9 | 14 | 16 | 19 | 15 | |
| Depression (%) | 17 | 17 | 19 | 10 | 20 | 42 | 17 | 17 | 18 | |
| Hypertension (%) | 35 | 31 | 64 | 33 | 36 | 52 | 56 | 40 | 25 | |
| AHI ≥5 (%) | 11 | 8 | 15 | 11 | 11 | 9 | 7 | 11 | 20 | |
| Sleep duration (%) | | | | | | | | | | |
| ≤5 h | 21 | 19 | 34 | 21 | 19 | 30 | — | — | — | |
| 5–6 h | 23 | 21 | 30 | 21 | 26 | 25 | — | — | — | |
| >6 h | 56 | 59 | 36 | 58 | 55 | 44 | — | — | — | |
| Sleep difficulty | | | | | | | | | | |
| Normal sleeping | 70 | 71 | 66 | — | — | — | 70 | 66 | 72 | |
| Poor sleep | 22 | 22 | 24 | — | — | — | 20 | 26 | 22 | |
| Insomnia | 8 | 7 | 10 | — | — | — | 11 | 8 | 6 | |

Data are means ± SD unless indicated otherwise and are adjusted for sampling weight. AHI, apnea-hypopnea index.

tory data as the standard to adjust the numbers of both the men and women in terms of BMI and race to be more representative of the national population.

Logistic regression models were used to assess the independent associations of the three-level sleep difficulty complaints and objective sleep duration with diabetes. We adjusted for major confounding factors expected to affect this relationship (i.e., age, race, sex, BMI, smoking status, alcohol consumption, depression, and SDB). We further tested the interaction between sleep difficulty complaints and objective sleep duration using a −2 log-likelihood ratio test in logistic regression models. Because the interaction between sleep difficulty complaints and objective sleep duration was not significant, we entered these two variables into the model separately, except for the last model (Model 3, Table 2), in which the results were adjusted for each other. Then we performed final logistic regression models to include eight dummy variables to represent all nine possible combinations of sleep difficulty and sleep duration and used persons without insomnia/poor sleep and with ≥6 h of sleep duration as a common reference group (Table 3).

RESULTS — The demographic, clinical, and sleep characteristics of the entire sample and its subgroups, based on sleep difficulty, and the three levels of objective sleep duration and diabetes, are presented in Table 1. Insomnia was associated with a significantly higher risk for diabetes (odds ratio [OR] 1.84 [95% CI 1.05–3.20], *P* < 0.05) in the first basic covariable adjusted model (Model 1, Table 2). With the increases in the number of potential confounding factors in the model, the OR of insomnia and diabetes remained very similar (changed <8%, from 1.84 to 1.69), but the precision of the estimation worsened, reflected by increased width of 95% CI. Poor sleep was associated with a slight, nonsignificant increase of risk for diabetes. Finally, an objective sleep duration of 5–6 h was associated with a slight, nonsignificant increase of risk for diabetes (1.35 [0.92–1.98]).

The risk of diabetes was synergistically and significantly increased among persons with both insomnia and short sleep duration (Table 3). The presence of both insomnia and an objective sleep duration ≤5 h increased the odds for diabetes by about 300% (OR 2.95 [95% CI

Table 2—Multivariable adjusted ORs (95% CIs) of diabetes associated with insomnia or objective sleep duration

| | Model 1 | Model 2 | Model 3 |
|--------------------|------------------|------------------|------------------|
| Sleep difficulty | | | |
| Normal sleeping | 1.00 | 1.00 | 1.00 |
| Poor sleep | 1.31 (0.91–1.90) | 1.23 (0.84–1.80) | 1.22 (0.83–1.78) |
| Insomnia | 1.84 (1.05–3.20) | 1.70 (0.95–3.02) | 1.69 (0.95–3.02) |
| Sleep duration (h) | | | |
| >6 | 1.00 | 1.00 | 1.00 |
| 5–6 | 1.38 (0.94–2.02) | 1.37 (0.93–2.00) | 1.35 (0.92–1.98) |
| ≤5 | 1.15 (0.77–1.71) | 1.11 (0.74–1.65) | 1.08 (0.72–1.61) |

Model 1: adjusted for age, race, sex, BMI, and sampling weight. Model 2: adjusted for age, race, sex, BMI, sampling weight, smoking, alcohol consumption, depression symptoms, and SDB. The interaction between insomnia and sleep duration was not statistically significant. Thus, these two variables were entered into the model separately, except for model 3, in which the results were adjusted for each other.

1.24–7.05]) compared with the group who have no insomnia/poor sleep complaint and slept for >6 h. In addition, the joint effect of insomnia and a sleep duration of 5–6 h increased the odds for diabetes by ~200% (2.07 [0.68–6.37]). The association in subjects with poor sleep and a short sleep duration was not significant.

Finally, objective short sleep duration in the absence of a sleep complaint was associated with nonsignificant increased odds for diabetes. The ORs remained very similar to those reported in Table 3 after we adjusted for number of wakes, number of sleep stage changes, percentage of stage 1 sleep, and periodic limb movements.

Table 3—Multivariable adjusted ORs (95% CIs) of diabetes associated with insomnia and objective sleep duration

| Sleep difficulty and duration | Adjusted OR (95% CI)* |
|-------------------------------|-----------------------|
| Normal sleeping | |
| >6 h | 1.00 |
| 5–6 h | 1.45 (0.91–2.30) |
| <5 h | 1.10 (0.68–1.79) |
| Poor sleep | |
| >6 h | 1.52 (0.87–2.65) |
| 5–6 h | 1.55 (0.80–3.01) |
| <5 h | 1.06 (0.53–2.15) |
| Insomnia | |
| >6 h | 1.10 (0.40–3.03) |
| 5–6 h | 2.07 (0.68–6.37) |
| <5 h | 2.95 (1.24–7.03) |

Interaction between insomnia and sleep duration is not statistically significant, $P = 0.75$. *Adjusted for age, race, sex, BMI, sampling weight, smoking, alcohol consumption, depression symptoms, and SDB.

CONCLUSIONS— This is the first study to demonstrate that chronic insomnia associated with objectively measured short sleep duration is a clinically significant risk factor for type 2 diabetes. This increased risk is independent of comorbid conditions frequently associated with insomnia or diabetes, such as age, race, obesity, alcohol consumption, smoking, SDB, periodic limb movements, or depression. Furthermore, our findings suggest that objective measures of sleep duration in insomnia may be a useful marker of the biological severity and medical impact of the disorder.

Several studies have examined the association of “sleep disturbances” with diabetes with inconsistent findings (13–16,19). However, none of these studies obtained objective sleep data or controlled for sleep apnea, a major confounder, both for sleep disturbance and increased incidence of type 2 diabetes.

In our study, the more severe insomnia (i.e., complaint of insomnia for at least 1 year) was significantly associated with higher odds of diabetes in the basic adjusted model. Most important, severe insomnia in combination with an objective sleep duration of <5 h was associated with a 300% higher odds for diabetes than the subjects who did not have a sleep complaint and slept for ≥ 6 h. The second highest odds ratio was found in the group of insomniacs who slept 5–6 h, although the association did not reach significance. These findings are consistent with the data on insomnia and hypertension, for which the strongest associations were found in these two groups (5). Further, these data are consistent with our hypothesis and previous physiological studies, which showed that the HPA axis and sym-

pathetic system activity is elevated in insomniacs with objective short sleep duration (6–11).

Insomnia based solely on clinical criteria and after adjustment for multiple variables was not associated with significant odds for diabetes. This finding is consistent with the results of the Sleep Heart Health Study (SHHS) (20). Further, the milder form of insomnia, i.e., poor sleep combined with short sleep duration, was not associated with a significant risk for diabetes. This lack of significance may reflect, given the large confidence intervals, a relatively small number of patients with diabetes in each subgroup and/or lack of use of more sensitive measures of glycemic status, i.e., a standard oral glucose challenge, in our study. An alternative explanation is that a larger degree of sleep disturbance is required to affect glycemic status compared with blood pressure, as is the case with sleep apnea for which an association with diabetes has been reported only in those with more severe apnea (21).

Experimental studies have shown that acute or short-term modest sleep loss is associated with impaired glycemic control (22) and inflammation, a condition that predisposes an individual to diabetes (23). In this study in a general population sample, we did not observe an association between objective sleep duration and diabetes. Several limitations may have resulted in this lack of significance, such as a relatively small number of patients with diabetes in each of the nine subgroups (combination of insomnia complaints and objective sleep measures), lack of more sensitive measures of glycemic status (i.e., oral glucose tolerance test), and a single night sleep recording, which may not be representative of the subjects' typical sleep patterns. Notably, all previous studies that have reported an association between sleep duration and diabetes were based on subject self-report (22). Additional studies that include both subjective and objective sleep measures and more sensitive methods of glycemic status should be conducted to address the issue of long-term sleep restriction and diabetes.

The data on the association of insomnia with hypertension and diabetes, as well as previous reports on insomnia and the stress system (6–8) and the autonomic system (9–11), provide the basis for a meaningful subtyping of chronic insomnia based on objective duration of sleep. One subtype is associated with

physiological hyperarousal, i.e., short sleep duration, activation of the stress system, and significant medical sequelae, such as hypertension and/or diabetes. The other subtype is not associated with physiological hyperarousal, i.e., normal sleep duration, normal activity of the stress system, and lack of significant medical sequelae. The diagnostic validity and utility of this subtyping should be tested in future studies.

The objective sleep duration in this study was based on one night of polysomnography, which may not be representative of the subjects' habitual sleep duration. However, in our previous studies, the association between objective sleep duration and hypercortisolemia was based on a four consecutive night sleep laboratory protocol, which should better represent the typical sleep profile of the subjects (6,7). It should be noted that, in our study, we investigated the relative sleep duration measured objectively (i.e., <5 h of objective sleep is relatively shorter than >6 h of sleep). Objective sleep duration was used as an internally valid marker of the severity of insomnia and not as a recommended optimal sleep duration for the general population, which is beyond the scope of our study.

Finally, the proposed criterion of >7 h as the cutoff point for "normal" sleep duration is based on self-reported duration, whereas in large epidemiological studies, i.e., the SHHS or Coronary Artery Risk Development in Young Adults (CARDIA) study, the average objective sleep duration is ~6 h, which is very similar to that of our sample (24,25). This duration is independent of whether sleep was recorded at home (SHHS) (24) or for 3 consecutive nights with actigraphy (CARDIA study) (25) or in the sleep laboratory (Penn State Cohort) (17,18). The consistency of the findings on the role of objective sleep duration in predicting insomnia severity between the physiological studies with multiple night recordings (6,7) and the current epidemiological study based on a single night recording increases our confidence about the replicability and generalizability of the present findings. Future researchers should explore the association between insomnia, sleep duration, and diabetes using multiple night recordings. Finally, our study is cross-sectional and does not provide causality in terms of the direction of the association. However, based on large amounts of clinical and research data, which have documented that insomnia is associated

with physiological hyperarousal (2,6–11), the most likely direction is that insomnia leads to diabetes.

In summary, insomnia with short sleep duration is associated with a significant risk for diabetes to a degree comparable to that for the other most common sleep disorder, i.e., SDB (21). Given the high prevalence of the disorder in the general population and the widespread misconception that this is a disorder of the "worried well," its diagnosis and appropriate treatment should become the target of public health policy. Objective measures of sleep duration of insomnia may serve as clinically useful predictors of the medical severity of chronic insomnia, and there is a need for validation of practical, easy-to-use, inexpensive methods, e.g., actigraphy, to measure sleep duration outside of the sleep laboratory. Finally, insomnia with objective short sleep duration may represent a phenotype within chronic insomnia that may respond differentially to treatment.

Acknowledgments— This research was funded in part by the National Institutes of Health (Grants R01HL 51931, R01HL 40916, and R01HL 64415).

No potential conflicts of interest relevant to this article were reported.

We thank Barbara Green for overall preparation of the manuscript.

References

1. National Institutes of Health. NIH state of the science statement on manifestations and management of chronic insomnia in adults. *J Clin Sleep Med* 2005;1:412–421
2. Basta M, Chrousos GP, Vela-Bueno A, Vgontzas AN. Chronic insomnia and the stress system. *Sleep Med Clin* 2007; 2:279–291
3. Phillips B, Mannino DM. Do insomnia complaints cause hypertension or cardiovascular disease? *J Clin Sleep Med* 2007; 3:489–494
4. Phillips B, Bůžková, Enright P, Cardiovascular Health Study Research Group. Insomnia did not predict incident hypertension in older adults in the Cardiovascular Health Study. *Sleep* 2009;32:65–72
5. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. *Sleep* 2009;32:491–497
6. Vgontzas AN, Tsigos C, Bixler EO, Stratakis CA, Zachman K, Kales A, Vela-Bueno A, Chrousos GP. Chronic insomnia

and activity of the stress system: a preliminary study. *J Psychosom Res* 1998; 45:21–31

7. Vgontzas AN, Bixler EO, Lin HM, Prolo P, Mastorakos G, Vela-Bueno A, Kales A, Chrousos GP. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. *J Clin Endocrinol Metab* 2001;86:3787–3794
8. Rodenbeck A, Cohrs S, Jordan W, Huether G, Růther E, Hajak G. The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. *Psychopharmacology* 2003;170:423–428
9. Stepanski E, Glinn M, Zorick F, Roehrs T, Roth T. Heart rate changes in chronic insomnia. *Stress Med* 1994;10:261–266
10. Bonnet MH, Arand DL. 24-hour metabolic rate in insomniacs and matched normal sleepers. *Sleep* 1995;18:581–588
11. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. *Psychosom Med* 1998;60:610–615
12. Aurora RN, Punjabi NM. Sleep apnea and metabolic dysfunction: cause or co-relation? *Sleep Med Clin* 2007;2:237–250
13. Meisinger C, Heier M, Loewel H, MONICA/KORA Augsburg Cohort Study. Sleep disturbance as a predictor of type 2 diabetes mellitus in men and women from the general population. *Diabetologia* 2005; 48:235–241
14. Mallon L, Broman JE, Hetta J. High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. *Diabetes Care* 2005;28:2762–2767
15. Kawakami N, Takatsuka N, Shimizu H. Sleep disturbance and onset of type 2 diabetes. *Diabetes Care* 2004;27:282–283
16. Nilsson PM, Růst M, Engström G, Hedblad B, Berglund G. Incidence of diabetes in middle-aged men is related to sleep disturbances. *Diabetes Care* 2004;27:2464–2469
17. Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: I. Prevalence and severity. *Am J Respir Crit Care Med* 1998; 157:144–148
18. Bixler EO, Vgontzas AN, Lin HM, Ten Have T, Rein J, Vela-Bueno A, Kales A. Prevalence of sleep-disordered breathing in women: effects of gender. *Am J Respir Crit Care Med* 2001;163:608–613
19. Björkelund C, Bondyr-Carlsson D, Lapidus L, Lissner L, Månsson J, Skoog I, Bengtsson C. Sleep disturbances in midlife unrelated to 32-year diabetes incidence. *Diabetes Care* 2005;28:2739–2744
20. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, Nieto FJ. Association of sleep time with dia-

- betes mellitus and impaired glucose tolerance. *Arch Intern Med* 2005;165:863–868
21. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE, Sleep Heart Health Study Investigators. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. *Am J Epidemiol* 2004;160:521–530
22. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. *J Appl Physiol* 2005;99:2008–2019
23. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, Chrousos GP. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. *J Clin Endocrinol Metab* 2004;89:2119–2126
24. Silva GE, Goodwin JL, Sherrill DL, Arnold JL, Bootzin RR, Smith T, Walsleben JA, Baldwin CM, Quan SF. Relationship between reported and measured sleep times: the Sleep Heart Health Study (SHHS). *J Clin Sleep Med* 2007;3:622–630
25. Lauderdale DS, Knutson KL, Yan LL, Rathouz PJ, Hulley SB, Sidney S, Liu K. Objectively measured sleep characteristics among early-middle-aged adults: the CARDIA study. *Am J Epidemiol* 2006;164:5–16